alignment seems to result in more balanced load distribution and kinematics more closely resembling the native knee. From a kinematic point of view, it is not recommended to place the tibia in more than 3° of varus. LEVEL OF EVIDENCE Biomechanical study.BACKGROUND The incidence of atypical oncologic failure in patients with bladder cancer, including peritoneal carcinomatosis, and recurrences at the port site and soft tissue after laparoscopic and robot-assisted radical cystectomy are not well characterized. METHODS We retrospectively reviewed the records of 52, 51, and 12 patients who underwent open, laparoscopic, and robot-assisted radical cystectomy, respectively, for bladder cancer from 2007 to 2018 at our institution. https://www.selleckchem.com/products/blz945.html We identified techniques associated with atypical oncologic failure. RESULTS The median follow-up period was 29&nbsp;months. Among the 115 patients, 29 (25%) experienced oncological recurrences, and 7 (6%), 12 (10%), and 23 (20%) had atypical, local, and distant recurrences, respectively. The laparoscopic and robot-assisted radical cystectomy groups had significantly higher incidences of total atypical oncologic failure than the open radical cystectomy group (p?=?0.013), including six, one, and two patients with peritoneal carcinomatosis, port site carcinomatosis, and soft tissue involvement, respectively. All 7 patients with atypical oncologic failure died of cancer; the median time from surgery to death was 9.3&nbsp;months. All these patients were cT&nbsp;≧&nbsp;3 and had grade 3 disease. In three patients (43%), the pathological tissue contained variants other than urothelial carcinoma. Five (71%) were among the initial twenty patients. Four patients (57%) had histories of intraoperative urine spillage or bladder perforation during transurethral resection. CONCLUSIONS Patients with cT&nbsp;≧&nbsp;3 stage, with pathological variants other than urothelial carcinoma, and those undergoing procedures that lead to extravesical dissemination should avoid laparoscopic radical cystectomy when the procedures are first introduced.Microaggressions perpetuate inequalities and stereotypes against people from marginalized communities. Research demonstrates that ongoing experiences of identity-related microaggressions can negatively impact mental health outcomes, increase somatic symptoms, and increase negative affect. This study explores the relationship between experiences of ableist microaggressions and mental health outcomes among disabled adults by using a quantitative cross-sectional survey of 311 U.S. adults who identify as disabled/having a disability, to examine the correlation between ableist microaggressions (using the AMS-65) and mental health (assessed by the MHI-18). Findings indicate that increased experiences ableist microaggressions are negatively correlated with positive mental health outcomes, and that the visibility of disabilities/impairments are correlated with experiencing ableist microaggressions. These findings can inform the work of counselors, therapists, social workers, and other human service professionals when supporting disabled individuals, recognizing that their mental health may be related to these common and often unintentional oppressive interactions.INTRODUCTION Immune checkpoint inhibitors (ICIs) are approved in multiple indications for cancer care. Most of the clinical trials have not questioned shorter than until disease progression approaches. In this study, we present results from a cohort of multiple advanced cancers treated with restricted anti-PD-(L)1 therapy. METHODS All patients with advanced cancers treated with anti-PD-(L)1 therapy outside clinical trials at Oulu University Hospital 2014-19 were retrospectively identified from pharmacy records. Clinical variables, treatment history and survival were collected. RESULTS 106 patients with median age of 66&nbsp;years with lung cancer (n?=?45, 42.5%), melanoma (n?=?30, 28.3%), renal and bladder cancers (GU cancers) (n?=?26, 24.5%), head and neck (H&amp;N) cancer (n?=?4, 3.8%), and colorectal cancer (n?=?1, 0.9%) were included in the study. The median (m) OS for the whole population was 14&nbsp;months (CI 9.7-18.3), 9&nbsp;months (CI 6.3-11.7) for patients with no IO-free period (n?=?64, 62.1%), and 27.0&nbsp;months (CI 20.6-33.4, p?=?0.000001) for patients (n?=?39) with IO-free period. The mIO-free survival was 10.0&nbsp;months (CI 7.1-12.9) for the whole cohort, 8.0&nbsp;months (CI 1.7-14.3) for lung cancer, 23.0&nbsp;months (CI 2.6-43.4) for melanoma, and 14.0&nbsp;months (CI 0.0-20.4) for GU cancer. From the IO-free cohort, 19 patients needed re-treatment during follow-up, of which 8 were re-challenged with anti-PD-(L)1 therapy. The clinical benefit rate of anti-PD-(L)1 re-challenge was 37.5%. CONCLUSIONS Our study shows that long IO-free periods can be achieved with limited duration of anti-PD-(L)1 therapy with excellent survival outcomes, and that anti-PD-(L)1 re-challenge is feasible in clinical practice.INTRODUCTION Major histocompatibility complex (MHC) plays an important role in colorectal cancer (CRC) immunity. However, the function of MHC class I chain-related B (MICB) molecule is not very clear. In this study, we explored the prognostic effect of MICB in colorectal cancer. MATERIAL AND METHODS From 2008-05 to 2012-11, consecutive CRC patients of Zhongshan Hospital, Fudan University were retrospectively enrolled as primary cohort. The inclusion criteria were as follows receiving primary radical resection, pathologically confirmed colorectal adenocarcinoma, no treatment before surgery, clinicopathological data available. Another cohort of CRC patients were collected from a public dataset GSE39582 of GEO database from 1987 to 2007 in the same criteria for validation. MICB was detected using immunochemistry and evaluated as prognostic biomarker. The cut-off value of MICB expression was calculated using X-tile software. RESULTS Finally, 863 patients were enrolled in the primary cohort, and 556 patients were enrolled in the validation cohort. MICB expression was significantly associated with tumor size and primary histological type in primary cohort, and with primary tumor location and distant metastases in validation cohort. The survival analysis showed that patients with high MICB expression had significantly better overall survival in both primary (P?=?0.002) and validation (P?=?0.001) cohorts. The multivariate analysis also confirmed that high MICB expression was a significantly independent protective factor for overall survival in both primary (hazard ratio HR?=?0.741, 95% CI 0.594-0.924) and validation (HR?=?0.699, 95% CI 0.508-0.961) cohorts. CONCLUSION For stage I-IV CRC patients, MICB was confirmed a novel independent prognostic factor. It could help better stratification of CRC prognosis.